Non-canonical BRAF variants and rearrangements in hairy cell leukemia.

IF 2 4区 医学 Q3 ONCOLOGY
Oncology Research Pub Date : 2024-08-23 eCollection Date: 2024-01-01 DOI:10.32604/or.2024.051218
Stephen E Langabeer
{"title":"Non-canonical <i>BRAF</i> variants and rearrangements in hairy cell leukemia.","authors":"Stephen E Langabeer","doi":"10.32604/or.2024.051218","DOIUrl":null,"url":null,"abstract":"<p><p>Hairy cell leukemia (HCL) is an uncommon mature B-cell malignancy characterized by a typical morphology, immunophenotype, and clinical profile. The vast majority of HCL patients harbor the canonical <i>BRAF</i> V600E mutation which has become a rationalized target of the subsequently deregulated RAS-RAF-MEK-MAPK signaling pathway in HCL patients who have relapsed or who are refractory to front-line therapy. However, several HCL patients with a classical phenotype display non-canonical <i>BRAF</i> mutations or rearrangements. These include sequence variants within alternative exons and an oncogenic fusion with the <i>IGH</i> gene. Care must be taken in the molecular diagnostic work-up of patients with typical HCL but without the <i>BRAF</i> V600E to include investigation of these uncommon mechanisms. Identification, functional characterization, and reporting of further such patients is likely to provide insights into the pathogenesis of HCL and enable rational selection of targeted inhibitors in such patients if required.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"32 9","pages":"1423-1427"},"PeriodicalIF":2.0000,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361905/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32604/or.2024.051218","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Hairy cell leukemia (HCL) is an uncommon mature B-cell malignancy characterized by a typical morphology, immunophenotype, and clinical profile. The vast majority of HCL patients harbor the canonical BRAF V600E mutation which has become a rationalized target of the subsequently deregulated RAS-RAF-MEK-MAPK signaling pathway in HCL patients who have relapsed or who are refractory to front-line therapy. However, several HCL patients with a classical phenotype display non-canonical BRAF mutations or rearrangements. These include sequence variants within alternative exons and an oncogenic fusion with the IGH gene. Care must be taken in the molecular diagnostic work-up of patients with typical HCL but without the BRAF V600E to include investigation of these uncommon mechanisms. Identification, functional characterization, and reporting of further such patients is likely to provide insights into the pathogenesis of HCL and enable rational selection of targeted inhibitors in such patients if required.

毛细胞白血病中的非典型 BRAF 变异和重排。
毛细胞白血病(HCL)是一种不常见的成熟 B 细胞恶性肿瘤,具有典型的形态、免疫表型和临床特征。在复发或对一线疗法难治的 HCL 患者中,绝大多数 HCL 患者都携带典型的 BRAF V600E 突变,这种突变已成为 RAS-RAF-MEK-MAPK 信号通路随后失调的合理靶点。然而,一些具有典型表型的 HCL 患者会出现非典型 BRAF 突变或重排。其中包括替代外显子内的序列变异以及与 IGH 基因的致癌融合。在对典型 HCL 但不伴有 BRAF V600E 的患者进行分子诊断时,必须注意包括对这些不常见机制的调查。对更多此类患者的鉴定、功能特征描述和报告很可能会有助于深入了解 HCL 的发病机制,并在必要时为此类患者合理选择靶向抑制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncology Research
Oncology Research 医学-肿瘤学
CiteScore
4.40
自引率
0.00%
发文量
56
审稿时长
3 months
期刊介绍: Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信